Holen Sie sich die Stockscreener-App
3.0659
1.22%
0.0369
Handel nachbörslich:
3.05
-0.0159
-0.52%
Schlusskurs vom Vortag:
$3.029
Offen:
$3.04
24-Stunden-Volumen:
12,006
Relative Volume:
0.66
Marktkapitalisierung:
$7.02M
Einnahmen:
$2.98M
Nettoeinkommen (Verlust:
$-2.68M
KGV:
-1.8976
EPS:
-1.6157
Netto-Cashflow:
$-2.29M
1W Leistung:
+5.72%
1M Leistung:
+0.52%
6M Leistung:
+18.83%
1J Leistung:
+0.66%
1-Tages-Spanne:
$2.98
$3.10
1-Wochen-Bereich:
$2.75
$3.10
52-Wochen-Spanne:
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Firmenname
Xenetic Biosciences Inc
Sektor
Branche
Telefon
781-778-7720
Adresse
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.0659 | 6.94M | 2.98M | -2.68M | -2.29M | -1.6157 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-01-08 | Eingeleitet | Maxim Group | Buy |
Xenetic Biosciences Inc Aktie (XBIO) Neueste Nachrichten
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesPre-Earnings Drift - Newser
Xenetic Biosciences Shares Edge Down Ahead of ASCO Update - Bez Kabli
Xenetic Biosciences (XBIO) Q2 2025 Earnings Roar: $-0.45 EPS Tops Street ViewCommunity Momentum Stocks - Newser
Xenetic Biosciences (XBIO) Declines -3.75% Amid Market Weakness 2026-05-18Community Watchlist Picks - Newser
Contact Us – Inside INdiana BusinessXenetic Biosciences, Inc.Common Stock (Nasdaq:XBIO) Stock Quote - FinancialContent
TradingKey - TradingKey
Renaissance Holdings Reports 137,440 XBIO Shares (NASDAQ: XBIO) - Stock Titan
Xenetic (XBIO) Reports Strong Q1 Revenue Growth - GuruFocus
Xenetic Virtually Unchanged - Baystreet.ca
Xenetic Biosciences Reports Q1 2026 Results: Advances DNase Oncology Platform, Grows Royalty Revenue, and Strengthens Financial Position - Minichart
Xenetic Biosciences' Q1 royalty revenue rises, net loss narrows - TradingView
Xenetic Biosciences Q1 2026: Royalty Revenue Up 36%, Net Loss Narrows to $0.5M - TradingView
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform - ACCESS Newswire
Xenetic Biosciences (NASDAQ: XBIO) Q1 2026 results show higher royalties, lower loss - Stock Titan
Cancer study OK, smaller loss put Xenetic’s DNase therapy in focus - Stock Titan
Xenetic Biosciences: Q1 Earnings Snapshot - marketscreener.com
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Strategic review and smaller loss at Xenetic Biosciences (NASDAQ: XBIO) - Stock Titan
Xenetic’s Next Test: An ASCO Readout And The Cash Question - Finimize
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Times Herald
Xenetic Biosciences Grants Equity Award to Interim CEO - The Globe and Mail
Xenetic Biosciences, Inc. Files Form 8-K Announcing Restricted Stock Award Agreement for CEO James Parslow - Minichart
Xenetic Biosciences, Inc. 2025 Annual Report 10-K/A: Executive Compensation, Governance, and Shareholder Information - Minichart
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting - Times Argus
Xenetic Biosciences (NASDAQ: XBIO) updates CEO pay, ownership in 10-K/A - Stock Titan
Xenetic Biosciences (NASDAQ: XBIO) grants CEO/CFO 100,000 restricted shares - Stock Titan
Xenetic Biosciences (XBIO) interim CEO awarded 100,000-share restricted stock grant - Stock Titan
Cancer drug research from Xenetic gets June poster slot at ASCO - Stock Titan
Xenetic Biosciences (XBIO) Stock: Pricing Analysis (Momentum Fading) 2026-04-20Resistance Breakout - Xã Vĩnh Công
Xenetic Biosciences Inc (XBIOW) - Minichart
Xenetic Biosciences (XBIO) Stock Rallies on Launch (Bullish Sentiment) 2026-04-15Real-time Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Investment Report: Can Xenetic Biosciences Inc maintain sales growth2026 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Published on: 2026-04-13 21:59:57 - baoquankhu1.vn
XBIO Q2 2025 Earnings: Xenetic Biosciences Inc. beats EPS views, reports zero revenueCrowd Consensus Signals - Newser
History Review: Is Xenetic Biosciences Inc stock good for income investors2026 Patterns & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Sectors Review: Is Xenetic Biosciences Inc stock undervalued right nowTrade Risk Summary & Verified Momentum Watchlists - baoquankhu1.vn
Loss Report: Is Xenetic Biosciences Inc a potential multi baggerWeekly Risk Report & Risk Controlled Stock Alerts - baoquankhu1.vn
XBIO PE Ratio & Valuation, Is XBIO Overvalued - Intellectia AI
XBIO.WS (Xenetic Biosciences) PB Ratio : (As of Apr. 04, 2026) - gurufocus.com
XBIO Q4 Earnings: Beats Estimates by $0.20 - Newser
Highs Report: Is now the right time to enter Xenetic Biosciences Inc2026 PreEarnings & Weekly High Conviction Ideas - baoquankhu1.vn
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update - Defense World
Published on: 2026-03-27 18:33:00 - baoquankhu1.vn
Aug Volume: Is Xenetic Biosciences Inc on track to beat earningsQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Analyst Calls: Can Xenetic Biosciences Inc be recession proof2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Xenetic (XBIO) Reports Increased Revenue and Advances Clinical D - GuruFocus
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results - Bitget
[8-K] Xenetic Biosciences, Inc. Reports Material Event | XBIO SEC FilingForm 8-K - Stock Titan
Cancer biotech Xenetic grows Takeda royalties to $3M, trims costs - Stock Titan
Xenetic Biosciences: Fourth Quarter Financial Results Overview - Bitget
Xenetic Biosciences 2025 Annual Report: Advancing DNase Immuno-Oncology Technology for Solid Tumors and Strategic Business Developments - Minichart
Finanzdaten der Xenetic Biosciences Inc-Aktie (XBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):